• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.

    2/4/25 12:02:28 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    AGIOS PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock, par value $0.001 per share (the "Shares")

    (Title of Class of Securities)


    00847X104

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    422,479.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    422,479.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    422,479.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital Institutional Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    480,410.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    480,410.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    480,410.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital Institutional Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    141,724.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    141,724.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    141,724.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital Institutional Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    52,905.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    52,905.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    52,905.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Four Crossings Institutional Partners V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    97,097.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    97,097.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    97,097.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital Offshore Investors II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    866,239.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    866,239.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    866,239.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital (AM) Investors, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    62,523.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    62,523.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    62,523.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Capital F5 Master I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    222,073.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    222,073.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    222,073.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Healthcare Partners Master, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    3,329,016.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    3,329,016.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,329,016.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Partners, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,452,393.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,452,393.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,452,393.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Institutional (GP) V, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    97,097.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    97,097.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    97,097.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon F5 (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    222,073.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    222,073.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    222,073.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Farallon Healthcare Partners (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    3,329,016.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    3,329,016.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,329,016.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Dapice Joshua J.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Dreyfuss, Philip D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Dunn Hannah E.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Fried, Richard B
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Gehani, Varun N.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Giauque, Nicolas
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Kim, David T.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Linn, Michael G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Luo Patrick (Cheng)
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Patel, Rajiv A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Roberts, Jr., Thomas G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Saito Edric C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Seybold, William
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Short Daniel S.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Spokes, Andrew J. M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Warren, John R.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00847X104


    1Names of Reporting Persons

    Wehrly, Mark C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    5,674,466.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    5,674,466.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,674,466.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AGIOS PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    88 Sidney Street, Cambridge, Massachusetts, 02139
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons." (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"), with respect to the Shares held by it; (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"), with respect to the Shares held by it; (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"), with respect to the Shares held by it; (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"), with respect to the Shares held by it; (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"), with respect to the Shares held by it; (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"), with respect to the Shares held by it; (vii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"), with respect to the Shares held by it; (viii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"), with respect to the Shares held by it; and (ix) Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership ("FHPM"), with respect to the Shares held by it. FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the "Farallon Funds." (x) Farallon Partners, L.L.C., a Delaware limited liability company (the "Farallon General Partner"), which is the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of each of the FCIP V General Partner (as defined below) and the FHPM General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI. (xi) Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the "FCIP V General Partner"), which is the general partner of FCIP V, with respect to the Shares held by FCIP V. (xii) Farallon F5 (GP), L.L.C., a Delaware limited liability company (the "F5MI General Partner"), which is the general partner of F5MI, with respect to the Shares held by F5MI. (xiii) Farallon Healthcare Partners (GP), L.L.C., a Delaware limited liability company (the "FHPM General Partner"), which is the general partner of FHPM, with respect to the Shares held by FHPM. (xiv) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, with respect to the Shares held by the Farallon Funds: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Richard B. Fried ("Fried"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Rajiv A. Patel ("Patel"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); William Seybold ("Seybold"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Luo, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons." Effective January 1, 2025, Luo became a managing member of the Farallon General Partner and a manager of each of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner. Accordingly, as of that date, Luo may be deemed a beneficial owner of the Shares held by the Farallon Funds.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
    (c)Citizenship:

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share (the "Shares")
    (e)CUSIP No.:

    00847X104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. The Shares reported hereby for the Farallon Funds are held directly by the Farallon Funds. The Farallon General Partner, as the general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds other than F5MI. The FCIP V General Partner, as the general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares held by FCIP V. The F5MI General Partner, as the general partner of F5MI, may be deemed to be a beneficial owner of all such Shares held by F5MI. The FHPM General Partner, as the general partner of FHPM, may be deemed to be a beneficial owner of all such Shares held by FHPM. Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.
    (b)Percent of class:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c). The Reporting Persons neither disclaim nor affirm the existence of a group among them. Each Reporting Person is a beneficial owner only of the securities reported by it on its cover page.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Farallon Capital Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Farallon Capital Institutional Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Farallon Capital Institutional Partners II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Farallon Capital Institutional Partners III, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Four Crossings Institutional Partners V, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:02/04/2025
     
    Farallon Capital Offshore Investors II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Farallon Capital (AM) Investors, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:02/04/2025
     
    Farallon Capital F5 Master I, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:02/04/2025
     
    Farallon Healthcare Partners Master, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:02/04/2025
     
    Farallon Partners, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member
    Date:02/04/2025
     
    Farallon Institutional (GP) V, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:02/04/2025
     
    Farallon F5 (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:02/04/2025
     
    Farallon Healthcare Partners (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:02/04/2025
     
    Dapice Joshua J.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Dreyfuss, Philip D.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Dunn Hannah E.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn
    Date:02/04/2025
     
    Fried, Richard B
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Gehani, Varun N.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Giauque, Nicolas
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Kim, David T.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Linn, Michael G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Luo Patrick (Cheng)
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Patel, Rajiv A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Roberts, Jr., Thomas G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Saito Edric C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Seybold, William
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Short Daniel S.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Spokes, Andrew J. M.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Warren, John R.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
     
    Wehrly, Mark C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:02/04/2025
    Exhibit Information

    Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k) Exhibit 2. Power of Attorney for Patrick (Cheng) Luo

    Get the next $AGIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    11/17/2022$17.00 → $32.00Sell → Neutral
    Goldman
    7/27/2022$33.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fouse Jacqualyn A converted options into 15,933 shares and sold $194,172 worth of shares (7,497 units at $25.90), increasing direct ownership by 6% to 149,220 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      4/10/25 4:02:58 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:18:52 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Viswanadhan Krishnan

      3 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:15:46 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

      Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

      2/17/22 2:39:08 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

      Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

      3/22/21 5:06:31 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    See more

    $AGIO
    Financials

    Live finance-specific insights

    See more
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Agios Appoints Catherine Owen to Board of Directors

      – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

      5/25/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Appoints Jeffrey Capello to Board of Directors

      – Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. "Agios is dedicated to cultivating a diverse board that is focused on the company's long-term value creation for patients and shareholders. As such, we are thrilled to welcome Jeff, whose nearly 30-year track record of driving profitab

      4/19/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

      CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About AgiosAgios is the pioneering leader in PK act

      4/17/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securitie

      2/13/25 6:31:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

      CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to devel

      5/9/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

      CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to dev

      5/2/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

      10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 10:26:14 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 6:32:25 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Agios Pharmaceuticals Inc.

      DEFA14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      4/25/25 4:05:10 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/14/24 3:44:53 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/8/24 2:40:47 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      2/14/24 2:21:13 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Agios Pharma with a new price target

      H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

      2/24/25 7:01:42 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Agios Pharma

      Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform

      10/16/24 8:38:23 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Agios Pharma with a new price target

      Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00

      10/10/24 8:30:27 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care